Monashee Investment Management LLC Invests $1.92 Million in SAB Biotherapeutics, Inc. $SABS

Key Points

• Monashee Investment Management disclosed a new position in SAB Biotherapeutics, buying 500,000 shares worth about $1.92 million in the first quarter. The stake represented roughly 0.98% of the company.
• SAB Biotherapeutics has seen mixed trading and fundamentals, with shares recently down 1.6% to $3.58 and the company reporting a quarterly loss of $0.35 per share, worse than analyst estimates.
• Wall Street sentiment remains cautiously bullish: analysts have assigned a Moderate Buy rating overall, with a consensus price target of $12.00 despite some downgrades and mixed opinions.

Monashee Investment Management LLC acquired a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 500,000 shares of the company's stock, valued at approximately $1,915,000. Monashee Investment Management LLC owned approximately 0.98% of SAB Biotherapeutics as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. acquired a new position in SAB Biotherapeutics during the first quarter worth about $29,000. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $30,000. Dimensional Fund Advisors LP purchased a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $32,000. State of Wyoming acquired a new stake in SAB Biotherapeutics during the 4th quarter valued at $34,000. Finally, Virtu Financial LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at $40,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 1.6%

NASDAQ SABS opened at $3.58 on Thursday. SAB Biotherapeutics, Inc. has a 12 month low of $1.85 and a 12 month high of $5.15. The company has a 50-day moving average of $3.70 and a 200-day moving average of $3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The company has a market cap of $273.73 million, a P/E ratio of -1.70 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, equities analysts predict that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SABS. Zacks Research raised SAB Biotherapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 11th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a "buy" rating and a $11.00 price objective for the company. Weiss Ratings reissued a "sell (d+)" rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Rodman & Renshaw reissued a "buy" rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.